K230074 is an FDA 510(k) clearance for the Rapid Aneurysm Triage and Notification. Classified as Radiological Computer-assisted Prioritization Software For Lesions (product code QFM), Class II - Special Controls.
Submitted by Ischemaview, Inc. (Golden, US). The FDA issued a Cleared decision on July 27, 2023 after a review of 198 days - an extended review cycle.
This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.2080 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Radiology review framework, consistent with the majority of Class II 510(k) submissions.
View all Ischemaview, Inc. devices